ICD-10-CM Billable Code

D03.72

Melanoma in situ of left lower limb, including hip

Clinical Classification Guidelines

Medical Intelligence & Overview

Melanoma in situ of the left lower limb, including the hip, is a type of skin cancer that is confined to the outermost layer of the skin. 'In situ' means that the cancer has not yet invaded deeper tissues, making early detection and treatment highly effective. This condition affects the skin on the left side of the lower limb, encompassing the area from just above the ankle up to the hip. Recognizing and understanding this early form of melanoma is crucial for effective management and positive outcomes.

Causes & Symptoms

Clinical Causes: Prolonged exposure to ultraviolet (UV) radiation from sun or tanning beds Having many moles or atypical moles Genetic predisposition and family history of skin cancer Exposure to environmental carcinogens History of sunburns, especially during childhood Immunosuppression due to certain medical conditions or medications

Key Symptoms: Appearance of a new pigmented lesion or mole on the skin Changes in the size, shape, or color of an existing mole Uneven borders of the pigmented area Multiple colors within the lesion, such as tan, brown, black, or even hints of blue or red Itching, tenderness, or bleeding in the affected area The lesion’s surface may be scaly or crusted Pigmented spots that enlarge or change rapidly over time

Diagnostic & Treatment

Diagnosis Path: Diagnosis typically involves a physical examination by a healthcare professional, focusing on the skin's appearance. If melanoma in situ is suspected, a biopsy is performed, where a small sample of tissue from the lesion is taken and examined microscopically. This confirms the diagnosis and helps determine the extent of the lesion. Imaging tests are usually not necessary unless there is concern about invasive disease, which is rare at this stage. Early diagnosis through routine skin checks can significantly improve treatment outcomes.

Treatment Protocols: Surgical excision: The primary treatment involves removing the lesion along with a margin of healthy tissue to ensure all abnormal cells are eliminated. Topical medications: In some cases, topical treatments like imiquimod cream may be used, though surgery remains the standard approach. Follow-up surveillance: Regular skin examinations to monitor for new or recurring lesions. Patient education: Guidance on sun protection measures, such as using broad-spectrum sunscreen, wearing protective clothing, and avoiding peak sun hours, to reduce future risk.

Reimbursement claims with a date of service on or after October 1, 2015 require the use of ICD-10-CM codes.

Clinical Advice & FAQs

Billing Guidance

Is D03.72 a billable ICD-10 code?
Yes, D03.72 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.

Documentation

How do I report D03.72?
Clinical documentation must specify the nature of Melanoma in situ of left lower limb, including hip and any associated comorbidities for accurate reporting.

Cite this Clinical Reference